• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Antipsychotic Use Associated With Increased Risk of Mortality

Antipsychotic Use Associated With Increased Risk of Mortality

March 11, 2021
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD. Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Gerhard T et al, PLoS One 2020;15(9):e0239206

TYPE OF STUDY: Population-based comparator cohort study

We know that atypical antipsychotics increase mortality in elderly patients with dementia—the FDA has long required a black box warning to that effect. But are these medications also dangerous when prescribed to younger people with depression?

To answer this question, researchers analyzed mortality rates of depressed adults (ages 25–64) enrolled in Medicaid between 2001–2010. Patients with major depression (but not other major Axis I disorders) who had failed to respond to > 3 months of antidepressant monotherapy were included. The researchers compared two cohorts: patients who had their antidepressant augmented with an antipsychotic (n = 22,410) vs those who had it augmented with a second antidepressant (n = 17,172). The outcome of interest was all-cause mortality rates over the next year for patients who remained on their medications.

In total, 105 deaths occurred during 7,601 person-years of follow-up in the antipsychotic augmentation cohort (138 per 100,000 person-years) versus 48 deaths during 5,727 person-years of follow-up in the antidepressant augmentation cohort (84 per 100,000 person-years). These numbers translate into an absolute risk of about 0.4% per year with antipsychotic augmentation, and a relative risk of 45% compared to antidepressant augmentation. To contextualize this figure, the relative risk in elderly patients with dementia is just slightly higher (around 54%), and this was concerning enough to the FDA to trigger a black box warning. Among the four antipsychotics with sufficient sample sizes, olanzapine and risperidone were associated with the highest risks of mortality, while quetiapine and aripiprazole the lowest—findings that are consistent with geriatric research.

The main weakness of the study was the lack of randomization, leaving open the possibility that prescribing bias could have contributed to the excess mortality in the antipsychotic augmentation group. For example, clinicians might have chosen atypicals for more severely depressed patients. Working in the opposite direction, however, clinicians might have preferred antidepressant augmentation for patients with medical comorbidities, which would artificially inflate mortality rates in this cohort instead. Furthermore, we should be cautious in generalizing results from Medicaid patients to the overall population.

TCPR’s Take
While this is only one study, and the increased mortality risk is small, the results should still give us pause before prescribing atypical antipsychotics in depression. It may be time to recalibrate their risk-benefit ratio.
General Psychiatry
KEYWORDS antidepressant-augmentation antipsychotics aripiprazole mortality
    Michael Posternak, MD.

    Psychological Benefits of Abstaining from Social Media

    More from this author
    www.thecarlatreport.com
    Issue Date: March 11, 2021
    SUBSCRIBE NOW
    Table Of Contents
    Stopping Psych Meds Part 2 TCPR, March 2021
    TMS Treatment for Depression: An Update
    How to Come Off a Psych Med Part 2: Antidepressants, Stimulants, and Benzos
    A Closer Look at Alpha-2 Agonists for ADHD
    Antipsychotic Use Associated With Increased Risk of Mortality
    In Brief: Who Needs the Therapeutic Alliance?
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.